Brief: Sequana Medical H1 EBIT Loss Widens To 6.8 Million Euros

Sequana Medical NV

25/09/2019 06:34

Sept 25 (Reuters) - SEQUANA MEDICAL NV  SEQUA.BR :
    * SEQUANA MEDICAL ANNOUNCES 2019 HALF YEAR RESULTS AND
YEAR-TO-DATE BUSINESS UPDATE
    * TOTAL LIQUIDITY POSITION OF EUR 12.9 MILLION AT END OF
JUNE 2019
COMPARED TO EUR 1.2 MILLION AT END OF JUNE 2018.
    * REITERATES ITS PREVIOUS GUIDANCE AND EXPECTS RESULTS OF
INVESTMENT IN EUROPEAN COMMERCIAL TEAM TO RESULT IN REVENUE
GROWTH VERSUS 2018
    * H1 REVENUES (EUR 0.41 MILLION) REMAINED RELATIVELY AT A
SIMILAR
LEVEL VERSUS SAME PERIOD LAST YEAR (EUR 0.45 MILLION)
    * EBIT EVOLVED FROM A LOSS OF EUR 4.76 MILLION IN HY 2018 TO
A
LOSS OF EUR 6.84 MILLION IN HY 2019
    * H2 WILL BE A PERIOD OF INTENSIVE CLINICAL ACTIVITY WITH A
KEY
FOCUS ON CAREFUL EXECUTION OF NORTH AMERICAN POSEIDON, EUROPEAN
PROMAS STUDIES
    * H1 NET LOSS FOR PERIOD EUR 7.3 MLN VS LOSS EUR 5.0 MLN
YEAR AGO

Source text for Eikon:  ID:nGNX2Tb0NT 
Further company coverage:  SEQUA.BR 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))